Omentin-1 vs Endomorphin-1
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Endomorphin-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Pain Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Tyr-Pro-Trp-Phe-NH2 |
| Molecular Weight | ~35 kDa | 610.71 Da |
| Half-Life | hours | Minutes in plasma |
| Amino Acids | 313 | 4 |
| Typical Dose | No approved human dose; research use only | 0.1-10 ug per animal |
| Route | IV|SC | Intrathecal / subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 600 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Endomorphin-1 Benefits
- ✓mu-opioid selectivity
- ✓potent antinociception
- ✓endogenous peptide scaffold
- ✓useful for receptor-discovery studies
Omentin-1 Dosing
not established|not established
Endomorphin-1 Dosing
Intrathecal 0.1-10 ug per animal|Subcutaneous 0.1-5 ug per animal|In vitro 0.1-100 nM
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Endomorphin-1 Side Effects
- ⚠respiratory depression at high exposure
- ⚠sedation
- ⚠tolerance and dependence potential
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Endomorphin-1
Endomorphin-1 is a key research peptide in studies of endogenous mu-opioid signaling and spinal analgesia. Like other peptide analgesics, its main translational hurdles are enzymatic instability, limited oral bioavailability, and delivery across barriers.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.